BYSI - ビヨンドスプリング (BeyondSpring Inc.)

BYSIのニュース

   During The Past Six Months, BeyondSpring Inc. (NASDAQ: BYSI) Shares Took An -88.09% Jump. Here Is What We Should Expect  2022/04/23 18:00:00 Marketing Sentinel
During the last session, BeyondSpring Inc. (NASDAQ:BYSI)’s traded shares were 0.32 million, with the beta value of the company hitting 1.01. At the end of the trading day, the stock’s price was $1.95, reflecting an intraday gain of 3.72% or $0.07. The 52-week high for the BYSI share is $33.00, that puts it down -1592.31 … During The Past Six Months, BeyondSpring Inc. (NASDAQ: BYSI) Shares Took An -88.09% Jump. Here Is What We Should Expect Read More »
   Li Auto, Luckin Coffee and BeyondSpring headline a SEC watch list for accounting compliance  2022/04/21 19:33:16 Seeking Alpha
The SEC added 17 more firms to the Holding Foreign Companies Accountable Act list of companies. Read more about the watch list.
   BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2021 Results - Earnings Call Transcript  2022/04/14 17:06:06 Seeking Alpha
BeyondSpring Inc. (NASDAQ:NASDAQ:BYSI) Q4 2022 Earnings Conference Call April 14, 2022, 08:00 AM ET Company Participants Ashley Sierchio - LifeSci Advisors Lan Huang - Co-Founder, Chairman…
   BeyondSpring Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:BYSI)  2022/04/14 16:56:48 Seeking Alpha
The following slide deck was published by BeyondSpring Inc.
   Beyondspring, Inc. (BYSI) Q4 2021 Earnings Call Transcript  2022/04/14 13:50:03 AlphaStreet
Beyondspring, Inc. (NASDAQ: BYSI) Q4 2021 earnings call dated Apr. 14, 2022 Presentation: Operator Good morning, and welcome to BeyondSpring’s Fourth Quarter and Year End 2012 Financial Results Conference Call…. […] The post Beyondspring, Inc. (BYSI) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .
   BeyondSpring Inc.s (BYSI) Volatility Reaches 6.26%: Dont Be Comfortable  2022/02/12 15:00:00 Stocks Register
BeyondSpring Inc. (NASDAQ:BYSI) price on Friday, February 11, fall -4.81% below its previous days close as a downside momentum from buyers pushed the stocks value to $2.97. A look at the stocks price movement, the close in the last trading session was $3.12, moving within a range at $2.945 and $3.145. The beta value (5-Year BeyondSpring Inc.s (BYSI) Volatility Reaches 6.26%: Dont Be Comfortable Read More »
   BeyondSpring Inc. (NASDAQ:BYSI), 8.79% Above Its High, Could Make A Strong Comeback.  2022/02/05 16:30:00 Marketing Sentinel
In last trading session, BeyondSpring Inc. (NASDAQ:BYSI) saw 0.32 million shares changing hands with its beta currently measuring 1.09. Company’s recent per share price level of $3.07 trading at $0.08 or 2.68% at ring of the bell on the day assigns it a market valuation of $113.01M. That closing price of BYSI’s stock is at … BeyondSpring Inc. (NASDAQ:BYSI), 8.79% Above Its High, Could Make A Strong Comeback. Read More »
   BeyondSpring, Beyond Salvage  2022/02/03 22:59:19 Seeking Alpha
   BeyondSpring Cuts On-Third Of Its Workforce  2022/01/12 10:43:50 Benzinga
BeyondSpring Inc (NASDAQ: BYSI ) plans to reduce its U.S. workforce by 35% , including reassignment of certain personnel to subsidiaries, which is expected to result in cost savings that will extend the cash runway. The reorganization follows the Full story available on Benzinga.com
   BeyondSpring''s New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia  2021/12/15 15:23:52 Benzinga
BeyondSpring Inc (NASDAQ: BYSI ) announced new data highlighting the mechanism of action of plinabulin in preventing chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) Annual Meeting and Exposition. The comparison was made between cancer patients receiving plinabulin 40 mg Full story available on Benzinga.com
   Long-termism as Investment Philosophy: Healthcare Investor Sangel Capital Expects to See Big Rise in Investment Value  2021/09/21 02:00:00 PR Newswire Asia (English)
SHENZHEN, China , Sept. 20\1, 2021 /PRNewswire/ -- The portfolio value of Sangel Capital ("Sangel" or the "Company"), a leading biotech and healthcare venture capital company based in China , is poised for strong growth as multiple biotech and pharmaceutical companies backed by Sangel''s venture funds have reported a succession of milestone achievements in 2021 that led to a substantial surge in their market valuation. The optimistic projection of Sangel Capital''s investment value came after the announcement of BeyondSpring''s positive topline results from its DUBLIN -3 registrational trial of plinabulin in August and the IPO plans of its portfolio companies earlier this year, including Denovo Biopharma, 3D Medicines and Sirnaomics. Over the past decade, Sangel Capital has grown into a leading venture investor and breakthrough company builder across the entire value chain of healthcare and biotech investment. "The past decade has seen us participate in an extensive range of investment opportunities spanning biomedicine, medical devices, healthcare, and biotech with most projects already yielding returns.
   BeyondSpring posts biggest intraday loss after trial data; H.C. Wainwright cuts price target  2021/09/20 19:32:02 Seeking Alpha
   Why Are BeyondSpring''s Shares Plunging Today?  2021/09/20 18:22:49 Business Insider Markets
BeyondSpring Pharmaceuticals Inc (NASDAQ: BYSI ) shared the final intention-to-treat (ITT) dataset from its DUBLIN-3
   Why Are BeyondSpring''s Shares Plunging Today?  2021/09/20 18:22:48 Benzinga
BeyondSpring Pharmaceuticals Inc (NASDAQ: BYSI ) shared the final intention-to-treat (ITT) dataset from its DUBLIN-3 Phase 3 trial of plinabulin. The trial evaluated plinabulin combined with docetaxel vs. docetaxel alone for 2nd/3rd line non-small cell lung cancer (NSCLC) patients with EGFR wild type. The data were presented at the European Society for Medical Oncology Congress ( ESMO21 ) 2021 failed to impress. The mean overall survival (OS) for the combination Full story available on Benzinga.com
   Heres why BeyondSpring shares are up more than 25% on Monday  2021/09/20 17:14:54 Invezz
Shares of BeyondSpring Inc (NASDAQ: BYSI) gained more than 200% in August as the pharmaceutical company said its candidate drug (Plinabulin) improved life expectancy for patients with advanced lung cancer. This morning, however, the stock tanked over 25% as STAT (American health-oriented news website) published an article that said issues with the conduct and analysis [] The post Heres why BeyondSpring shares are up more than 25% on Monday appeared first on Invezz.

calendar